France Just Approved IV Ketamine for Suicidal Crisis. The US Has an Excuse, Not an Answer.

---

title: “France Just Approved IV Ketamine for Suicidal Crisis. The US Has an Excuse, Not an Answer.” slug: france-iv-ketamine-suicidal-crisis-us-gap-2026 post_type: daily_pulse primary_category: science-medicine substance_category: dissociatives lens: [science, policy] tags: [ketamine, depression, suicide-prevention, fda, dissociatives] meta_description: “France’s ANSM issued the world’s first national authorization of IV ketamine for adult acute suicidal crisis. The US approved esketamine in 2019 but has never standardized the faster, cheaper IV racemic form—because no company will pay for the trials.” read_time_minutes: 3 schema_type: NewsArticle sources:

• url: https://www.clinicaltrialvanguard.com/article/psych-pulse/france-just-approved-what-the-u-s-still-wont-name-iv-ketamine-for-acute-suicidal-crisis/ title: “France Just Approved What the U.S. Still Won’t Name: IV Ketamine for Acute Suicidal Crisis” publisher: Clinical Trial Vanguard source_tier: B published_date: 2026-03-15
• url: https://www.midcitytms.com/the-difference-between-ketamine-and-esketamine-spravato-for-depression-treatment/ title: “Understanding Esketamine vs Ketamine for Treatment-Resistant Depression in 2026” publisher: Mid City TMS source_tier: C
• url: https://www.spravato.com/ title: “SPRAVATO® (esketamine): A Prescription Nasal Spray” publisher: Janssen / Johnson & Johnson source_tier: C ai_generated: true

---

In March 2026, France’s Agence nationale de sécurité du médicament et des produits de santé became the first national drug regulator anywhere in the world to issue an authorization for intravenous racemic ketamine specifically indicated for adults in acute suicidal crisis. Not off-label, not under a compassionate use exception, not left to individual emergency department discretion—authorized. Named. Given a protocol, a dosing standard, and a regulatory status that clinicians can point to.

Emergency psychiatrists in the US watched from the other side of a gap that is entirely structural and entirely self-inflicted.

Ketamine has been used off-label in emergency departments for years—in France, in the UK, in Australia, in US hospitals whose attending psychiatrists were willing to use their discretion. The data on IV racemic ketamine for suicidal ideation is not absent. Multiple small trials and case series have documented rapid, often dramatic reduction in suicidal ideation within hours of a single infusion—a time frame that no existing approved antidepressant approaches. For a patient in acute crisis admitted to an emergency department, the difference between an antidepressant that might work in six weeks and a medication that reduces active suicidal ideation within four hours is not a clinical nuance. It is the question of whether someone survives to have the six-week conversation.

The United States approved esketamine—the S-enantiomer of racemic ketamine, delivered as a nasal spray under the brand name Spravato—in 2019 for treatment-resistant depression and in 2020 for major depressive disorder with acute suicidal ideation. Spravato requires administration in a certified healthcare setting, under medical supervision, for at least two hours following each dose, as part of a REMS program that limits its availability to enrolled outpatient clinics. It is effective. It costs significantly more than racemic ketamine, requires a more elaborate infrastructure, and has a different pharmacokinetic profile that, for some patients and some situations, makes IV racemic ketamine the better option. The FDA has also issued warnings about compounded ketamine used outside REMS oversight, adding further regulatory fog to the landscape.

IV racemic ketamine is a generic. It has been off-patent for decades. No pharmaceutical company has the financial incentive to run the large, expensive Phase III trials needed to get it an FDA indication, because the return on that investment would accrue to every hospital that buys a vial, not to the company that funded the research. This is a structural failure of the drug approval system, not a scientific uncertainty. The evidence is sufficient to support clinical use; what’s missing is the commercial motivation to formalize it. The result: in the United States, whether a person in suicidal crisis has access to IV ketamine depends on which emergency department they arrive at, whether the treating physician uses it, and whether the hospital’s legal and compliance teams have signed off. It’s a roulette wheel where the stakes are lives.

France standardized the roulette wheel. The ANSM reviewed the evidence, concluded that IV racemic ketamine is the standard of care for adult acute suicidal crisis, and issued the authorization that gives every French emergency physician the regulatory backing to use it. That’s what national drug regulation is supposed to do. Emergency psychiatrists in the US are watching the ANSM’s outcomes data closely. If the protocol shows the population-level results the smaller trials have suggested, the pressure on the FDA to follow will build—but through a process that will take years, not months, and will require either a sponsor with the resources to fund a confirmatory Phase III trial or a reform of how orphan-compound indications work in the US approval system. Until then, the gap is real, the fix is known, and the barrier is entirely financial.

Until then, the gap is real, the fix is known, and the barrier is entirely financial.